Canadian National PDA Treatment Study

Key facts

Sponsor

IWK Health Centre

Principal Investigator

Souvik Mitra, MD, MSc

IWK Health Center, Halifax, Canada

Intervention

Indomethacin(drug)

Enrollment

1663 enrolled

Eligibility

All sexes

Timeline

2020 – 2023

Study locations (22)

• Foothills Medical Centre, Calgary, Alberta, Canada
• Royal Alexandra Hospital, Edmonton, Alberta, Canada
• Royal Columbian Hospital, New Westminster, British Columbia, Canada
• British Columbia Women's Hospital, Vancouver, British Columbia, Canada
• Victoria General Hospital, Victoria, British Columbia, Canada
• Health Sciences Centre, Winnipeg, Manitoba, Canada
• St. Boniface General Hospital, Winnipeg, Manitoba, Canada
• The Moncton Hospital, Moncton, New Brunswick, Canada
• Saint John Regional Hospital, Saint John, New Brunswick, Canada
• IWK Health Center, Halifax, Nova Scotia, Canada
• Kingston Health Sciences Centre, Kingston, Ontario, Canada
• London Health Sciences Centre, London, Ontario, Canada
• Children's Hospital of Eastern Ontario, Ottawa, Ontario, Canada
• Hospital for Sick Children, Toronto, Ontario, Canada
• Mount Sinai Hospital, Toronto, Ontario, Canada
• +7 more locations on ClinicalTrials.gov

Collaborators

Provincial Health Services Authority British Columbia · Children's Hospital of Eastern Ontario · CHU de Quebec-Universite Laval · Foothills Medical Centre · Victoria General Hospital · The Hospital for Sick Children · Health Sciences Centre, Winnipeg, Manitoba · St. Justine's Hospital · Queen's University · MOUNT SINAI HOSPITAL · Royal Alexandra Hospital · Regina General Hospital · Royal University Hospital Foundation · St. Boniface Hospital · The Moncton Hospital · Horizon Health Network · Sunnybrook Health Sciences Centre · Windsor Regional Hospital · Royal Columbian Hospital Foundation · Centre de recherche du Centre hospitalier universitaire de Sherbrooke · London Health Sciences Centre · Canadian Institutes of Health Research (CIHR)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Arterial duct anomaly

Additional recruiting or active studies for the same condition.

• ACTIVE NOT RECRUITINGNCT06950164
  Dynamic Changes of Ductus Arteriosus in < 31 Weeks Preterm Infants: an Observational Study
  Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
• RECRUITINGNCT06658496
  PDA for Kidneys Study
  University of Wisconsin, Madison
• RECRUITINGNCT06646250
  NeoDoppler: New Ultrasound Technology for Continuous Monitoring of Cerebral Circulation Pilot
  St. Olavs Hospital
• RECRUITINGPHASE2NCT07143201
  Precision Dosing of Oral Ibuprofen for PDA, A Pilot RCT
  Hamilton Health Sciences Corporation
• RECRUITINGNCT05264753
  Post Marketing Clinical Follow Up Study to Evaluate Efficacy and Safety of the Occlutech PDA Occluder in Patients With Patent Ductus Arteriosus Defects
  Occlutech International AB
• ACTIVE NOT RECRUITINGNCT04371081
  Amplatzer Piccolo Occluder Japan Post-marketing Database Surveillance
  Abbott Medical Devices
• ENROLLING BY INVITATIONNANCT04667455
  Improving Care for Children With Congenital Heart Disease.
  Lund University Hospital
• ACTIVE NOT RECRUITINGNCT03782610
  Early Prediction of Spontaneous Patent Ductus Arteriosus (PDA) Closure and PDA-Associated Outcomes
  Nationwide Children's Hospital

See all trials for Arterial duct anomaly →